普罗布考对急性冠脉综合征患者抗氧化、抗炎作用的研究

目的:观察普罗布考对急性冠脉综合征(ACS)患者血氧化低密度脂蛋白抗体(oxLDL-Ab)、高敏C反应蛋白(hs-CRP)和白介素18(IL-18)水平的影响。方法:ACS患者81例,随机分为普罗布考组(41例)和常规治疗组(40例),用药治疗前检测外周血oxLDL-Ab、hs-CRP和IL-18的水平,用药治疗1周后复查hs-CRP和IL-18,治疗4周后复查oxLDL-Ab,观察治疗前后各指标变化。并分析两组治疗结束前一周心绞痛发作的频率。结果:治疗后普罗布考组较常规治疗组oxLDL-Ab(56.20±14.56)U/ml∶(88.65±11.23)U/ml]、hs-CRP(8.78±5.61)mg/L∶(14.23±9.79)mg/L]及IL-18(88.54±17.74)pg/ml∶(141.83±19.52)pg/ml]浓度明显降低(P均0.05)。普罗布考组治疗第4周平均心绞痛发作频率较常规治疗组显著降低(2.5±1.5)次/周∶(4.7±1.7)次/周,P0.05],次数减少与oxLDL-Ab减少有明显相关性(r=0.60,P0.05)。结论:普罗布考对急性冠脉综合征患者具有抗氧化、抗炎作用,可减少心绞痛发作频率。

Effects of probucol on antioxidation and anti-inflammation in patients with acute coronary syndrome

Objective： To observe the effects of probucol on blood levels of oxidative low density lipoprotein antibody （oxLDL--Ab）, high sensitive C--reactive protein （hs--CRP） and interleukin- 18 （IL--18） in patients with acute coronary syndrome （ACS）. Methods： A total of 81 ACS patients were randomly divided into probucol group （n=41） and a routine treatment group （routine group, n=40）. Blood IL 18, oxLDL -Ab and hs--CRP levels were respectively measured before therapy. The level of oxLDL-- Ab was measured again after 4-- week treatment. The levels of hs--CRP and IL-- 18 were measured again after 1 week treatment. The frequencies of typical angina of probucol group and routine group in last week of treatment were analyzed. Results： The levels of oxLDL--Ab E （56.20±14.56） U/ml vs. （88.65±11.23） U/ml], hs--CRP （8.78±5.61） mg/L vs. （14.23±9.79） mg/L] and IL--18 （88.54 ±17.74） pg/ml vs. （141.83±19.52） pg/ml] were significantly lower in probucol group compared with those of routine group after treatment （P〈0.05 all）. The frequency of typical angina of probucol group in last week of treat- ment was significantly lower than that of routine group （2.5±1. 5） times vs. （4.7±1.7） times, P〈0.05], and it was closely correlated with the decreased oxLDL Ab value （r=0.60, P〈0.05）. Conclusion： Probucol possesses anti oxidant and anti inflammatory action and can decrease angina in patients with ACS.